NASDAQ : AVBP
ArriVent BioPharma, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 14.87 USD (Oct 30, 2026, 4:00 PM EST) · Market cap 733.21M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 733.21M |
| Enterprise Value | 360.44M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 49.31M |
| Shares Outstanding | 49.31M |
| Shares Change (YoY) | +30.39% |
| Shares Change (QoQ) | +5.63% |
| Owned by Insiders (%) | 1.82% |
| Owned by Institutions (%) | 66.81% |
| Float | 29.63M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 96.11 |
| PB Ratio | 1.96 |
| P/TBV Ratio | 2.00 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 14.16 |
| Quick Ratio | 13.40 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -53.25% |
| Return on Assets (ROA) | -33.11% |
| Return on Invested Capital (ROIC) | -35.64% |
| Return on Capital Employed (ROCE) | -47.96% |
| Weighted Average Cost of Capital (WACC) | 11.67% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.13M |
| Employee Count | 77 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.35 |
| 52-Week Price Change | -20.40% |
| 50-Day Moving Average | 24.75 |
| 200-Day Moving Average | 26.96 |
| Relative Strength Index (RSI) | 32.13 |
| Average Volume (20 Days) | 2,666,378 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 6.81M |
| Short Previous Month | 8.45M |
| Short % of Shares Out | 13.80% |
| Short % of Float | 22.97% |
| Short Ratio (days to cover) | 3.56 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -175.94M |
| Pretax Income | -164.21M |
| Net Income | -164.21M |
| EBITDA | n/a |
| EBIT | -175.94M |
| Earnings Per Share (EPS) | -$3.70 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 373.12M |
| Total Debt | 351,000 |
| Net Cash | 372.77M |
| Net Cash Per Share | $7.56 |
| Equity (Book Value) | 366.84M |
| Book Value Per Share | 7.59 |
| Working Capital | 366.33M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -147.93M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | -147.93M |
| FCF Per Share | -$3.00 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -30.39% |
| Shareholder Yield | -30.39% |
| Earnings Yield | -24.87% |
| FCF Yield | -20.18% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $25.80 |
| Price Target Difference | 73.50% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |